STOCK TITAN

Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags

Dyadic Applied BioSolutions (NASDAQ: DYAI) reported commercial and product milestones in Q3 2025, including milestone payments and progress across life sciences and food & nutrition programs.

Key discrete items: a $500,000 productivity milestone for recombinant human albumin with payment expected in Q4 2025, and a $250,000 milestone received from the Inzymes partnership after Q3 2025 productivity improvements. Proliant has begun sampling albumin with a commercial launch targeted in late 2025–early 2026. Dyadic also reported sampling/production starts for transferrin, research-grade DNase I meeting activity and purity benchmarks, and a signed term sheet for non-animal human alpha-lactalbumin for infant nutrition. Several enzyme candidates are advancing with scale-up on track for late 2025.

Dyadic Applied BioSolutions (NASDAQ: DYAI) ha riportato traguardi commerciali e di prodotto nel terzo trimestre 2025, inclusi pagamenti di milestone e progressi nei programmi di life sciences e di food & nutrition.

Elementi chiave: un milestone di produttività di 500.000 USD per l'albumina umana ricombinante con pagamento previsto nel Q4 2025, e un milestone di 250.000 USD ricevuto dalla partnership Inzymes dopo i miglioramenti di produttività nel Q3 2025. Proliant ha iniziato la fornitura di campioni di albumina con un lancio commerciale mirato per la fine del 2025–inizio 2026. Dyadic ha inoltre riportato l'avvio di campionamenti/produzione per la transferrina, DNase I di livello ricerca che raggiunge gli obiettivi di attività e purezza, e un term sheet firmato per l'alpha-lattalbumina umana non animale destinata all'alimentazione infantile. Diversi candidati enzimatici sono in avanzamento con lo scale-up in programma per la fine 2025.

Dyadic Applied BioSolutions (NASDAQ: DYAI) informó hitos comerciales y de producto en el tercer trimestre de 2025, incluidos pagos por hitos y avances en los programas de ciencias de la vida y alimentación y nutrición.

Elementos clave: un hito de productividad de 500.000 USD para la albúmina humana recombinante con pago esperado en el Q4 2025, y un hito de 250.000 USD recibido de la asociación Inzymes tras mejoras de productividad en el Q3 2025. Proliant ha comenzado a muestrear albúmina con un lanzamiento comercial previsto para finales de 2025 o principios de 2026. Dyadic también informó el inicio de muestreo/producción de transferrina, DNase I de grado investigación que cumple con los objetivos de actividad y pureza, y un term sheet firmado para la alfa-lactalbumina humana no animal destinada a nutrición infantil. Varios candidatos enzimáticos están avanzando con el escalado en curso para finales de 2025.

Dyadic Applied BioSolutions (NASDAQ: DYAI) 는 2025년 3분기에 상업적 및 제품 이정표를 발표했으며, 생명과학 및 식품/영양 프로그램 전반에 걸친 이정표 지불 및 진전을 포함합니다.

주요 이정표로는 재조합 인간 알부민 생산성 50만 달러의 이정표로, 2025년 4분기에 지급될 예정이며, Inzymes 파트너십으로부터 25만 달러의 이정표를 2025년 3분기 생산성 개선 후 수령했습니다. Proliant는 2025년 말~2026년 초 상업 출시를 목표로 알부민 샘플링을 시작했습니다. 또한 Dyadic는 트랜스페린의 샘플링/생산 시작, 연구급 DNase I의 활성 및 순도 벤치마크 충족, 영유아 영양용 비동물성 인간 α-락토알부민의 서명 계약서를 보고했습니다. 여러 효소 후보들이 진행 중이며 대량 생산은 2025년 말에 맞춰 규모 확대 중입니다.

Dyadic Applied BioSolutions (NASDAQ: DYAI) a annoncé des jalons commerciaux et produits au cours du troisième trimestre 2025, y compris des paiements liés à des jalons et des progrès dans les programmes de sciences de la vie et alimentation & nutrition.

Éléments clés : un jalon de productivité de 500 000 USD pour l'albumine humaine recombinante avec un paiement prévu au T4 2025, et un jalon de 250 000 USD reçu du partenariat Inzymes après les améliorations de productivité du T3 2025. Proliant a commencé à échantillonner l'albumine avec un lancement commercial visé pour fin 2025 – début 2026. Dyadic a également rapporté le démarrage des échantillonnages/productions pour la transferrine, la DNase I de grade recherche répondant aux objectifs d'activité et de pureté, et une term sheet signée pour l’alpha-lactalbumine humaine non animale destinée à l’alimentation infantile. Plusieurs candidats enzymatiques avancent avec l’augmentation à un rythme prévu pour fin 2025.

Dyadic Applied BioSolutions (NASDAQ: DYAI) meldete im Q3 2025 kommerzielle und Produktmeilensteine, darunter Meilensteinzahlungen und Fortschritte in den Programmen für Life Sciences sowie Food & Nutrition.

Wesentliche Einzelheiten: ein Produktivitäts-Meilenstein von 500.000 USD für rekombinantes menschliches Albumin mit Zahlung voraussichtlich im Q4 2025 und ein Meilenstein von 250.000 USD aus der Partnerschaft Inzymes nach Produktivitätsverbesserungen im Q3 2025. Proliant hat begonnen, Albumin zu sampeln, mit einem kommerziellen Markteinführungstermin für spät 2025–Frühjahr 2026. Dyadic meldete außerdem Start von Sampling/Produktion für Transferrin, forschungsnahes DNase I, das Aktivität und Reinheit erfüllt, und ein unterzeichnetes Termsheet für humane Alpha-Lactalbumin aus nicht tierischen Quellen für Säuglingsernährung. Mehrere Enzymkandidaten schreiten voran, das Scale-up ist für spät 2025 vorgesehen.

Dyadic Applied BioSolutions (بورصة ناسداك: DYAI) أبلغت عن معالم تجارية ومنتج في الربع الثالث من 2025، بما في ذلك دفعات معلمية وتقدم في برامج علوم الحياة والتغذية والطعام.

عناصر رئيسية: معلم إنتاجية قدره 500,000 دولار أمريكي لالألبومين البشري المعاد تكوينه مع توقع دفعه في الربع الرابع من 2025, ومعلم قدره 250,000 دولار تم استلامه من شراكة Inzymes بعد تحسينات الإنتاجية في الربع الثالث من 2025. بدأت Proliant في أخذ عينات من الألبومين مع هدف الإطلاق التجاري في أواخر 2025–بداية 2026. كما أفادت Dyadic أيضاً ببدء أخذ العينات/الإنتاج للترانفسيرين، DNase I البحثية التي تلبي معايير النشاط والنقاء، ومخطط شروط موقع لمصل alpha-lactalbumin البشري غير الحيواني لرعاية الرضع. تتقدم عدة مرشحين إنزيميين مع التوسع في نطاق الإنتاج المقرر لأواخر 2025.

Dyadic Applied BioSolutions (NASDAQ: DYAI) 在 2025 年第三季度公布了商业和产品里程碑,其中包括里程碑付款以及生命科学和食品与营养计划方面的进展。

关键事项:一个价值 50 万美元 的重组人血白蛋白生产力里程碑,预计在 2025 年第四季度 支付;以及来自 Inzymes 伙伴关系的 25 万美元 里程碑,在 2025 年第三季度生产力提升后收到。Proliant 已开始采样白蛋白,商业上市目标为 2025 年底–2026 年初。Dyadic 还报告了转铁蛋白的采样/生产启动、研究级 DNase I 达到活性和纯度基准,以及用于婴儿营养的非动物性人α-乳清蛋白的已签署条款书。若干酶候选正在推进,放大生产计划预计在 2025 年底 完成。

Positive
  • Received a $250,000 milestone payment in Q3 2025
  • Achieved a $500,000 productivity milestone for albumin; payment expected Q4 2025
  • Proliant began sampling recombinant human albumin; launch targeted late 2025–early 2026
  • DNase I met activity and purity benchmarks and entered research-grade production
  • Enzyme scale-up on track for late 2025
Negative
  • None.

Insights

Dyadic reports milestone payments and near-term commercial launches across life sciences and food markets.

Dyadic converts platform productivity into cash by selling protein/enzyme batches and licensing to partners like Proliant and Inzymes. Milestone receipts of $500,000 and $250,000 reflect validated productivity gains and progress from research supply to commercial scale. Sampling activity for albumin, transferrin, and DNase I indicates movement from R&D into OEM and direct-sales channels.

Outcomes depend on partner commercial launches, regulatory fit for infant nutrition, and timely scale-up. Payment timing and product launches remain contingent on partner sampling feedback and manufacturing scale milestones. The company cites a stronger balance sheet, but no specific financials are disclosed here.

Watch concrete milestones: the anticipated payment in Q4 2025, the late 2025 to early 2026 commercial launch window, and scale-up completion for the first enzyme. These items will confirm revenue conversion and commercial traction over the next 3–12 months.

JUPITER, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc., d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today announced the achievement of additional milestone payments in its collaborations with Proliant Health & Biologicals in life sciences and Inzymes ApS in food and nutrition, along with updates on its business transformation and commercial progress.

“Dyadic is advancing its transition to a commercially focused, revenue-driven company,” said Joe Hazelton, Dyadic Applied BioSolutions President and Chief Operating Officer. “The third quarter featured substantial progress throughout our portfolio, marked by notable achievements in partnerships with Proliant Health and Biologicals in the life sciences sector, as well as ongoing collaborations with Inzymes in food and nutrition. These accomplishments highlight the versatility and scalability of Dyadic’s protein production platforms across multiple markets. The company remains committed to capitalizing on near-term commercialization opportunities, supported by a stronger balance sheet and an expanding pipeline of both partner-led and internally developed products.”

Recent Company Developments

Life Sciences

  • Recombinant Human Albumin (Proliant Partnership): In Q3 2025, Dyadic reached a milestone in productivity, achieving a $500,000 milestone, with payment anticipated in Q4 2025. Additional revenue growth is expected as commercialization advances. Proliant has started sampling the product, with the commercial launch targeted for late 2025 and early 2026.
  • Recombinant Transferrin: Sampling efforts are expanding in research, diagnostic and cultured meat markets. Initial production of lab-grade non-animal transferrin products is underway to meet current OEM and supply opportunities. Validation is ongoing with research and diagnostic customers.
  • Recombinant DNase I (RNase-free): Dyadic’s DNase I has successfully met required performance benchmarks for activity and purity, validating its utility in molecular biology, diagnostics, and biopharma applications. Dyadic is currently producing its DNase I at research grade to support direct sales and OEM supply opportunities.

Food & Nutrition

  • Recombinant Alpha-Lactalbumin: A term sheet has been signed for the development of non-animal human alpha-lactalbumin for use in the infant nutrition market. Initial sampling of non-animal bovine alpha-lactalbumin for food and nutrition markets is in progress, and licensing discussions are underway with potential partners.
  • Non-Animal Dairy Enzymes (Inzymes Partnership): Dyadic received a $250,000 milestone payment following the achievement of productivity improvements in Q3 2025. The first enzyme’s scale-up is on track for a late 2025 launch, with additional enzyme candidates advancing as part of this partnership.

About Dyadic Applied BioSolutions

Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s C1 and Dapibus™ expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs. For more information about Dyadic, please visit www.dyadic.com.

Safe Harbor Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking statements involve many risks, uncertainties or other factors beyond Dyadic’s control. These factors include, but are not limited to, the following: (i) our history of net losses; (ii) market and regulatory acceptance of our microbial protein production platforms and other technologies; (iii) failure to commercialize our microbial protein production platforms or our other technologies; (iv) competition, including from alternative technologies; (v) the results of nonclinical studies and clinical trials; (vi) our capital needs; (vii) changes in global economic and financial conditions; (viii) our reliance on information technology; (ix) our dependence on third parties; (x) government regulations and environmental, social and governance issues; (xi) intellectual property risks; and (xii) our ability to comply with the listing standards of the Nasdaq Stock Market LLC. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com. All forward-looking statements speak only as of the date made, and except as required by applicable law, Dyadic assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in our expectations.

Contact:

Dyadic International, Inc.
Ping Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com


FAQ

How much did Dyadic (DYAI) receive from partnerships in Q3 2025?

Dyadic reported a $250,000 milestone payment received in Q3 2025 and a $500,000 milestone for albumin with payment expected in Q4 2025.

When is Dyadic's recombinant human albumin commercial launch expected for DYAI?

Proliant has started sampling and a commercial launch is targeted in late 2025–early 2026.

What progress did DYAI report for DNase I in Q3 2025?

Dyadic's DNase I met required activity and purity benchmarks and is being produced at research grade for sales and OEM supply.

What is the status of Dyadic's non-animal alpha-lactalbumin (DYAI) for infant nutrition?

Dyadic signed a term sheet for non-animal human alpha-lactalbumin development and is sampling bovine alpha-lactalbumin for food markets.

Which DYAI enzyme programs are advancing and when is scale-up planned?

Non-animal dairy enzymes under the Inzymes partnership advanced productivity with scale-up of the first enzyme on track for late 2025.
Dyadic Intl Inc Del

NASDAQ:DYAI

DYAI Rankings

DYAI Latest News

DYAI Latest SEC Filings

DYAI Stock Data

44.15M
27.05M
25.17%
13.88%
0.32%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
JUPITER